7122 Federal Register / Vol. 81, No. 27 / Wednesday, February 10, 2016 / Notices 

Model EBA 75 CCER for Mining. 

Pursuant to 42 CFR 84.301, 

manufacturers may continue to 

manufacture, label, and sell largecapacity CCERs approved under the 

former regulatory standard in subpart H 

(those CCERs with a rated service time 

of greater than 50 minutes) for mining, 

until 1 year after this approval date, or 

until January 4, 2017. 

All types of CCERs approved under 

subpart H that were manufactured and 

labeled as NIOSH-approved and sold by 

April 9, 2015, as well as those units 

manufactured and labeled as NIOSHapproved and sold during the extended 

time periods pursuant to § 84.301, may 

continue to be used as NIOSH-approved 

respirators until the end of their service 

life. 

Dated: February 1, 2016. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2016–02649 Filed 2–9–16; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number CDC–2016–0003; NIOSH 

057–A] 

Draft Criteria for a Recommended 

Standard: Occupational Exposure to 1- 

Bromopropane (1–BP); Notice of 

Public Meeting; Availability of Draft 

Document for Comment 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of public meeting and 

availability of draft document for public 

comment. 

SUMMARY: On September 16, 2009, the 

National Institute for Occupational 

Safety and Health (NIOSH), Centers for 

Disease Control and Prevention (CDC) 

announced in the Federal Register 

https://www.gpo.gov/fdsys/pkg/FR2009-09-16/pdf/E9-22297.pdf plans to 

evaluate the scientific data on 

1-bromopropane (1–BP) and to issue its 

findings on the potential health risks. A 

draft document entitled, Criteria for a 

Recommended Standard: Occupational 

Exposure to 1-Bromopropane (1–BP), 

has been developed which contains an 

assessment of toxicological data and 

provides recommendations for the safe 

handling of 1–BP-containing materials. 

NIOSH is seeking comments on the draft 

document and plans to have a public 

meeting to discuss the document. The 

draft document and instructions for 

submitting comments can be found at 

www.regulations.gov. 

DATES: The public meeting will be held 

on March 30, 2016, 9:00 a.m.–3:00 p.m. 

Eastern Time, or after the last public 

commenter has spoken, whichever 

occurs first. Comments must be received 

by April 29, 2016. 

ADDRESSES: The public meeting will be 

held at the NIOSH/CDC Robert A. Taft 

Laboratories, Auditorium, 1150 

Tusculum Avenue, Cincinnati, Ohio 

45226. 

FOR FURTHER INFORMATION CONTACT: G. 

Scott Dotson, NIOSH, Education and 

Information Division, Robert A. Taft 

Laboratories, 1090 Tusculum Avenue, 

Cincinnati, OH 45226, (513) 533–8540 

(not a toll free number). 

SUPPLEMENTARY INFORMATION: 

I. Background 

On September 16, 2009, the National 

Institute for Occupational Safety and 

Health (NIOSH), Centers for Disease 

Control and Prevention (CDC) 

announced in the Federal Register 

plans to evaluate the scientific data on 

1-bromopropane (1–BP) and to issue its 

findings on the potential health risks. 

The results of this evaluation are 

presented in the draft document, 

Criteria for a Recommended Standard: 

Occupational Exposure to 

1-Bromopropane (1–BP). The purpose of 

the public meeting and public comment 

period is to obtain comments on the 

draft document. Special emphasis will 

be placed on the following: 

• Whether the health hazard 

identification, risk estimation, and 

discussion of health effects of 1–BP are 

a reasonable reflection of the current 

understanding of the scientific 

literature; 

• Identifying workplaces and 

occupations where exposure to 1–BP 

may occur; 

• Identifying studies on health effects 

associated with occupational exposure 

to 1–BP that were not identified in the 

draft; 

• Identifying current strategies for 

controlling or preventing exposure to 1– 

BP (e.g., engineering controls, work 

practices, personal protective 

equipment); 

• Identifying current exposure 

measurement methods and challenges 

in measuring workplace exposures to 1– 

BP; and 

• Identifying areas for future 

collaborative efforts (e.g., research, 

communication, development of 

exposure measurement and control 

strategies). 

As part of the review of this draft 

criteria document, reviewers are asked 

to address the following critical 

questions: 

(1) Does the draft criteria document 

accurately identify and characterize the 

health hazards of occupational 

exposures to 1–BP based on the current 

understanding of the scientific 

literature? Please identify any additional 

relevant literature that NIOSH should 

consider when developing its 

recommendations. Is the risk estimation 

for 1–BP presented in the draft criteria 

document a reasonable reflection of the 

current understanding of the scientific 

literature? Please describe any changes 

in the risk estimation that NIOSH 

should consider and provide supporting 

scientific literature. 

(2) Are there other risk assessment 

methods or health endpoints that 

NIOSH should consider for estimating 

risks of 1–BP? Please provide 

supporting scientific literature or other 

evidence to support your 

recommendations. 

(3) In this draft criteria document, 

NIOSH proposes a recommended 

exposure limit (REL) to prevent a risk of 

one excess cancer in 1000 workers 

exposed to 1–BP for a 45-year working 

lifetime. During development of the 

draft criteria document, NIOSH also 

considered setting the REL at a level to 

prevent 1 excess cancer in 10,000 

workers for a 45-year working lifetime. 

Please comment on the excess cancer 

risk level and resulting REL for 1–BP. 

(4) Is the relationship between 

exposure to 1–BP and biological activity 

(toxicity) accurately presented in the 

draft criteria document? 

(5) Are the recommended strategies 

for controlling or preventing exposure to 

1–BP (e.g., engineering controls, work 

practices, personal protective 

equipment) reasonable and technically 

feasible? 

(6) Are there other techniques or 

technologies capable of controlling 

workplace exposures to 1–BP that 

should be discussed in the draft criteria 

document? 

(7) Are the exposure measurement 

methods and the associated challenges 

in measuring workplace exposures to 1– 

BP adequately addressed in the draft 

criteria document? 

(8) Are there medical screening and 

surveillance measures, such as specific 

diagnostic tests, guidelines, and metrics, 

that should be implemented for workers 

expected of being exposed to 1–BP that 

are not discussed in the draft criteria 

document? 


asabaliauskas on DSK9F6TC42PROD with NOTICES2
Federal Register / Vol. 81, No. 27 / Wednesday, February 10, 2016 / Notices 7123 

(9) Are there biological indices or 

metrics that should be used to aid in the 

interpretation of biomonitoring data for 

1–BP? What is the most appropriate 

biomarker that can confirm and quantify 

occupational exposures to 1–BP? 

(10) Should acute exposure 

recommendations, such as a short term 

exposure limit (STEL), be derived for 1– 

BP? If so, what data support the 

development of the STEL? 

(11) NIOSH provided Globally 

Harmonized System (GHS) of 

Classification and Labelling of 

Chemicals designations for health 

endpoints evaluated in the criteria 

document. Please comment on the 

utility of these classifications for hazard 

communication. Are these 

classifications helpful for employers? 

II. Public Meeting 

NIOSH will hold a public meeting on 

the draft document Criteria for a 

Recommended Standard: Occupational 

Exposure to 1-Bromopropane (1–BP) to 

allow commenters to provide oral 

comments on the draft document, to 

inform NIOSH about additional relevant 

data or information, and to ask 

questions on the draft document and 

NIOSH recommendations. 

This meeting is open to the public. 

Attendance is limited only by the space 

available. The meeting room 

accommodates 100 people. The meeting 

will be open to a limited number of 

participants through a conference call 

phone number and Webcast live on the 

Internet. 

Notification of intent to attend the 

meeting, for in-person and remote 

participation, must be made to the 

NIOSH Docket Office, at nioshdocket@

cdc.gov, (513) 533–8611, no later than 

March 16, 2016. Priority for attendance 

will be given to those providing oral 

comments. Other requests to attend the 

meeting will then be accommodated on 

a first-come, first-served basis. 

Registration is required for in-person 

attendance and remote participation. 

Because this meeting is being held at a 

federal site, pre-registration is required 

on or before March 16, 2016 and a 

government-issued photo ID (driver’s 

license, military ID or passport) will be 

required to obtain entrance to the 

facility. There will be an airport-type 

security check. Non-US citizens need to 

register by February 24, 2016 to allow 

sufficient time for mandatory facility 

security clearance procedures to be 

completed. This information will be 

transmitted to the CDC Security Office 

for approval. An email confirming 

registration will be sent from NIOSH for 

both in-person participation and audio 

conferencing participation. 

Oral comments will be permitted for 

15 minutes. If additional time becomes 

available, presenters will be notified. 

All requests to present should contain 

the name, address, telephone number, 

and relevant business affiliations of the 

presenter, topic of the presentation, 

whether you will be presenting in 

person or by phone, and the 

approximate time requested for the 

presentation. An email confirming 

registration will be sent from the NIOSH 

Docket Office and will include details 

needed to participate. Oral comments 

given at the meeting will be recorded 

and included in the docket. 

After reviewing the requests for 

presentations, NIOSH will notify the 

presenter when his/her presentation is 

scheduled. If a participant is not in 

attendance when his/her presentation is 

scheduled to begin, the remaining 

participants will be heard in order. After 

the last scheduled speaker is heard, 

participants who missed their assigned 

times may be allowed to speak, limited 

by time available. 

Attendees who wish to speak but did 

not submit a request for the opportunity 

to make a presentation may be given 

this opportunity after the scheduled 

speakers are heard, at the discretion of 

the presiding officer and limited by time 

available. 

You may submit comments, identified 

by CDC 2016–0003 and NIOSH 057–A, 

by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: National Institute for 

Occupational Safety and Health, NIOSH 

Docket Office, 1090 Tusculum Avenue, 

MS C–34, Cincinnati, Ohio 45226–1998. 

Instructions: All information received 

in response to this notice must include 

the agency name and docket number 

[CDC–2016–0003; NIOSH 057–A]. All 

relevant comments received will be 

posted without change to 

www.regulations.gov including any 

personal information provided. All 

information will be available for public 

examination and copying at the NIOSH 

Docket Office, 1150 Tusculum Avenue, 

Room 155, Cincinnati, Ohio 45226. 

Non-U.S. Citizens: Because of CDC 

Security Regulations, any non-U.S. 

citizen wishing to attend this meeting 

must provide the following information 

in writing to the NIOSH Docket Officer 

at the address below no later than 

February 24, 2016. 

Name: 

Gender: 

Date of Birth: 

Place of Birth (city, province, state, country): 

Citizenship: 

Passport Number: 

Date of Passport Issue: 

Date of Passport Expiration: 

Type of Visa: 

U.S. Naturalization Number (if a naturalized 

citizen): 

U.S. Naturalization Date (if a naturalized 

citizen): 

Visitor’s Organization: 

Organization Address: 

Organization Telephone Number: 

Visitor’s Position/Title within the 

Organization: 

This information will be transmitted 

to the CDC Security Office for approval. 

Visitors will be notified as soon as 

approval has been obtained. 

Public Review 

The external review of the draft 

document has been (1) developed in 

accordance with Office of Management 

and Budget (OMB) guidelines, (2) is 

consistent with NIOSH peer review 

practice, and (3) is meant to ensure that 

credible and appropriate science is 

reflected within the draft document. 

Dated: February 4, 2016. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2016–02650 Filed 2–9–16; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces a meeting for the initial 

review of applications in response to 

Funding Opportunity Announcement 

(FOA) DP16–004, Childhood Obesity 

Research Demonstration 2.0. 

Time and Date: 10:00 a.m.–6:00 p.m., 

EST, March 15–16, 2016 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to 

the public in accordance with 

provisions set forth in Section 

552b(c)(4) and (6), Title 5 U.S.C., and 

the determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Public Law 92– 

463. 

Matters for Discussion: The meeting 

will include the initial review, 

discussion, and evaluation of 

applications received in response to 

FOA DP16–004, Childhood Obesity 

Research Demonstration 2.0. 


asabaliauskas on DSK9F6TC42PROD with NOTICES2